Skip to main content
Article thumbnail
Location of Repository

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

By H Ueno, N Kaniwa, T Okusaka, M Ikeda, C Morizane, S Kondo, E Sugiyama, S R Kim, R Hasegawa, Y Saito, T Yoshida, N Saijo and J Sawada

Abstract

Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G>A [Ala70Thr]), and showed extremely low plasma cytidine deaminase activity and gemcitabine clearance. Our results suggest that homozygous *3 is a major factor causing gemcitabine-mediated severe adverse reactions among the Japanese population

Topics: Clinical Studies
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2661788
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.